Copeland Capital Administration LLC boosted its stake in shares of U.S. Bodily Remedy, Inc. (NYSE:USPH – Free Report) by 4.1% through the 2nd quarter, in accordance with its most up-to-date 13F submitting with the SEC. The agency owned 721,458 shares of the corporate’s inventory after shopping for a further 28,178 shares through the interval. U.S. Bodily Remedy makes up roughly 1.8% of Copeland Capital Administration LLC’s holdings, making the inventory its third largest holding. Copeland Capital Administration LLC owned 5.52% of U.S. Bodily Remedy price $87,578,000 as of its most up-to-date SEC submitting.
A number of different institutional buyers and hedge funds additionally lately made modifications to their positions in USPH. JPMorgan Chase & Co. lifted its holdings in shares of U.S. Bodily Remedy by 314.9% within the first quarter. JPMorgan Chase & Co. now owns 63,096 shares of the corporate’s inventory valued at $6,274,000 after buying a further 47,890 shares within the final quarter. Raymond James & Associates purchased a brand new stake in U.S. Bodily Remedy within the 1st quarter valued at roughly $279,000. Citigroup Inc. boosted its place in U.S. Bodily Remedy by 3.2% through the 1st quarter. Citigroup Inc. now owns 11,702 shares of the corporate’s inventory price $1,164,000 after buying a further 359 shares over the last quarter. MetLife Funding Administration LLC grew its stake in shares of U.S. Bodily Remedy by 61.1% through the 1st quarter. MetLife Funding Administration LLC now owns 7,102 shares of the corporate’s inventory price $706,000 after buying a further 2,693 shares within the final quarter. Lastly, Rhumbline Advisers raised its holdings in shares of U.S. Bodily Remedy by 44.9% within the first quarter. Rhumbline Advisers now owns 46,940 shares of the corporate’s inventory valued at $4,668,000 after buying a further 14,547 shares over the last quarter.
Insider Exercise at U.S. Bodily Remedy
In different U.S. Bodily Remedy information, Director Edward L. Kuntz bought 1,000 shares of the agency’s inventory in a transaction that occurred on Friday, August eleventh. The shares have been bought at a mean value of $109.95, for a complete transaction of $109,950.00. Following the completion of the sale, the director now instantly owns 9,280 shares within the firm, valued at $1,020,336. The sale was disclosed in a doc filed with the Securities & Trade Fee, which is out there at this hyperlink. In different information, COO Graham D. Reeve bought 4,114 shares of the enterprise’s inventory in a transaction dated Friday, August eleventh. The shares have been bought at a mean value of $109.99, for a complete worth of $452,498.86. Following the completion of the sale, the chief working officer now owns 7,577 shares of the corporate’s inventory, valued at $833,394.23. The sale was disclosed in a doc filed with the SEC, which is out there at this hyperlink. Additionally, Director Edward L. Kuntz bought 1,000 shares of the agency’s inventory in a transaction dated Friday, August eleventh. The inventory was bought at a mean value of $109.95, for a complete transaction of $109,950.00. Following the transaction, the director now instantly owns 9,280 shares within the firm, valued at $1,020,336. The disclosure for this sale could be discovered right here. Within the final 90 days, insiders have bought 6,114 shares of firm inventory price $670,049. Insiders personal 1.80% of the corporate’s inventory.
Analyst Scores Adjustments
USPH has been the subject of a number of analyst experiences. CJS Securities raised shares of U.S. Bodily Remedy from a “market carry out” score to an “outperform” score in a analysis report on Tuesday. StockNews.com upgraded U.S. Bodily Remedy from a “promote” score to a “maintain” score in a analysis word on Wednesday. Financial institution of America assumed protection on shares of U.S. Bodily Remedy in a analysis word on Friday, June thirtieth. They issued a “purchase” score and a $138.00 goal value for the corporate. Barrington Analysis boosted their goal value on shares of U.S. Bodily Remedy from $116.00 to $124.00 and gave the inventory an “outperform” score in a report on Monday, August 14th. Lastly, JPMorgan Chase & Co. started protection on shares of U.S. Bodily Remedy in a analysis word on Friday. They issued an “chubby” score and a $108.00 value goal for the corporate. One equities analysis analyst has rated the inventory with a maintain score and 4 have given a purchase score to the corporate’s inventory. In accordance with knowledge from MarketBeat, the inventory at present has a consensus score of “Average Purchase” and a consensus value goal of $123.33.
Learn Our Newest Inventory Evaluation on USPH
U.S. Bodily Remedy Inventory Efficiency
USPH opened at $94.74 on Friday. The corporate has a fast ratio of two.82, a present ratio of two.82 and a debt-to-equity ratio of 0.29. U.S. Bodily Remedy, Inc. has a 12-month low of $73.30 and a 12-month excessive of $124.11. The enterprise has a 50 day transferring common of $107.19 and a 200-day transferring common of $106.42. The inventory has a market cap of $1.42 billion, a price-to-earnings ratio of 49.09, a PEG ratio of 4.73 and a beta of 1.36.
U.S. Bodily Remedy (NYSE:USPH – Get Free Report) final introduced its quarterly earnings outcomes on Tuesday, August eighth. The corporate reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.02. U.S. Bodily Remedy had a return on fairness of 9.22% and a web margin of 5.25%. The enterprise had income of $151.50 million through the quarter, in comparison with the consensus estimate of $151.06 million. Throughout the identical quarter final 12 months, the agency posted $0.90 EPS. The corporate’s quarterly income was up 7.7% on a year-over-year foundation. On common, equities analysis analysts count on that U.S. Bodily Remedy, Inc. will submit 2.68 earnings per share for the present 12 months.
U.S. Bodily Remedy Pronounces Dividend
The enterprise additionally lately introduced a quarterly dividend, which was paid on Friday, September eighth. Traders of document on Friday, August 18th have been issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 1.82%. The ex-dividend date was Thursday, August seventeenth. U.S. Bodily Remedy’s payout ratio is 89.12%.
U.S. Bodily Remedy Profile
U.S. Bodily Remedy, Inc, by its subsidiaries, operates outpatient bodily remedy clinics that present pre-and post-operative care and remedy for orthopedic-related issues, sports-related accidents, preventative care, rehabilitation of injured employees, and neurological-related accidents.
See Additionally
Need to see what different hedge funds are holding USPH? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for U.S. Bodily Remedy, Inc. (NYSE:USPH – Free Report).
This prompt information alert was generated by narrative science know-how and monetary knowledge from MarketBeat in an effort to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you think about U.S. Bodily Remedy, you may wish to hear this.
MarketBeat retains monitor of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and U.S. Bodily Remedy wasn’t on the checklist.
Whereas U.S. Bodily Remedy at present has a “Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.
View The 5 Shares Right here
